Indaptus Therapeutics Announces Results From Second Cohort Of Phase 1 Trial; Initiates Multi-Dose Cohort
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics announced positive results from the second cohort of its Phase 1 trial for Decoy 20, leading to the initiation of a multi-dose cohort. The data from the single dose cohort is expected to be published at a scientific conference in 2024.

March 04, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics announced positive Phase 1 trial results for Decoy 20, leading to the initiation of a multi-dose cohort.
Positive results from clinical trials typically lead to increased investor confidence and can drive up the stock price. The initiation of a multi-dose cohort indicates progress in the drug's development, which is a positive signal for investors. The announcement of expected publication in 2024 also adds to the positive outlook by indicating ongoing advancements.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100